By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Blueprint Medicines 

Cambridge  Massachusetts  02140  U.S.A.
Phone: 617-585-2033 Fax: n/a



Company News
Blueprint Medicines (BPMC) Receives FDA Authorization To Proceed With Clinical Trials For Two Drug Candidates 7/13/2015 6:29:24 AM
Blueprint Medicines (BPMC) Added To Russell 2000, 3000 And Global Indexes 6/29/2015 7:04:06 AM
Blueprint Medicines (BPMC) Debuts Preclinical Data For First-In-Class RET Drug Candidate 6/22/2015 7:25:29 AM
Blueprint Medicines (BPMC) Reports First Quarter 2015 Financial Results 6/11/2015 10:30:37 AM
Blueprint Medicines (BPMC) To Present At Upcoming Investor Conferences In June 6/5/2015 7:22:34 AM
Blueprint Medicines (BPMC) Announces Closing of Initial Public Offering 5/5/2015 2:40:38 PM
As Market Froths, Blueprint Medicines (BPMC) Debuts $147 Million IPO for Massachusetts' Biggest Recent IPO 4/30/2015 6:14:42 AM
Blueprint Medicines Presents New Preclinical Data Demonstrating Its Drug Candidate BLU-554 Induces Significant Tumor Regression In Models Of Hepatocellular Carcinoma 4/24/2015 10:47:38 AM
Blueprint Medicines Presents New Preclinical Data Demonstrating Significant Anti-Tumor Activity Of BLU-285 In Treatment-Resistant GIST And On Novel Cancer Drug Targets 4/20/2015 6:07:42 AM
Fidelity CEO Uses Personal Fortune to Bet on Cancer Related IPOs Like Coherus, Adaptimmune and Blueprint Medicines 4/10/2015 6:06:18 AM